Inbec Tablet

The human body reacts differently to the Inbec tablet. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

Some of the common side effects of Inbec tablet are mentioned below:

• Headache
  
• Blood in urine
  
• Skin rash
  
• Itching
  
• Vomiting
  
• Nausea
  
• Diarrhea
  
• Dizziness
  
• Drowsiness
  
• Hair loss
  
• Fatigue

Take the dose of Inbec tablet as per your healthcare provider’s prescription. Do not stop taking the medicine suddenly, unless your doctor tells you. This medicine is given under the strict supervision of a doctor. Do not self-administer.

Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider. Inbec tablet can be taken without food or with food. The doctor will provide emergency medical treatment. You should not break, crush, or chew the medicine; it should be swallowed as a whole.

• Inbec tablet contains Indinavir, which is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). These inhibitors block the part of HIV called protease.
• HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1.
• Indinavir works to bind to the protease active site and inhibits the activity of the enzyme. Further, this inhibition prevents cleavage of the viral polyproteins, resulting in the formation of an immature non-infectious viral particle.
  

It is advisable to not skip a dose. If you miss a dose, make sure to take it as soon as you remember. However, if it is already time for your next scheduled dose, skip the missed dose and take the scheduled dose. Also, make sure to not increase the dose strength to catch up with the missed dose.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

• Gazzard B, Moecklinghoff C, Hill A. (2025).  New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom. Clinicoecon Outcomes Res. 4:193–200 - https://pubmed.ncbi.nlm.nih.gov/22888265/
  
• Kaufmann D, Pantaleo G, Sudre P, Telenti A. (2024). CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet. 351(9104):723–4 - https://pubmed.ncbi.nlm.nih.gov/9504519/
  
• Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, et al. (2024). A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. Italy, the Netherlands, Canada and Australia study. JAMA. 279(12):930–7.
  
• Olalla J, Pérez-Stachowski J, Tortajada B, Del Arco A, Márquez E, De la Torre J, Nieto M, García de Lomas JM, Prada JL, García-Alegría J. (2025). Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks. BMC Pharmacol Toxicol.19(1):63 - https://pubmed.ncbi.nlm.nih.gov/31272264/
  
• Pérez-Stachowski J, Tortajada B, Del Arco A, Márquez E, De la Torre J, Nieto M, García de Lomas JM, Prada JL, García-Alegría J, Olalla J. (2025). Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 48 weeks. Infect Dis (Lond). 51(9):691-693 - https://pubmed.ncbi.nlm.nih.gov/31272264/
  
• Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses MA, Kilby JM, Lutz T, Podzamczer D, Portilla J, Roth N, Wong D, Granier C, Wynne B, Pappa K. (2025). Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr. 70(5):515-9 - https://pubmed.ncbi.nlm.nih.gov/26262777/